TB-500

TB-500 is a synthetic peptide that represents the active region of Thymosin Beta-4, a 43-amino acid protein that is naturally present in virtually all human and animal cells. Thymosin Beta-4 plays a fundamental role in cell biology, primarily through its interaction with actin, a critical protein involved in cell structure and movement. The peptide's ability to regulate actin allows it to promote cell migration, which is essential for wound healing and tissue repair.

Research on Thymosin Beta-4 has demonstrated its involvement in multiple phases of tissue repair. It promotes angiogenesis, reduces inflammation, and can decrease scar tissue formation. In animal models, it has been shown to promote healing of skin wounds, corneal injuries, and cardiac tissue following myocardial infarction. The peptide appears to work by upregulating cell migration and differentiation, particularly of stem and progenitor cells to sites of injury.

TB-500 has a notable history in veterinary medicine, particularly in horse racing, where it has been used to treat tendon and ligament injuries. This equine use contributed to its recognition in the broader performance and wellness communities. The peptide's systemic distribution after injection means it can potentially reach injury sites throughout the body, which is considered an advantage over therapies that must be applied locally.

While the preclinical evidence base for Thymosin Beta-4 is substantial, human clinical trial data specifically for TB-500 remains limited. Some clinical research has been conducted on Thymosin Beta-4 for wound healing and dry eye syndrome. As with many research peptides, the gap between promising animal data and proven human efficacy remains a significant consideration.